<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377661</url>
  </required_header>
  <id_info>
    <org_study_id>V1-19012014</org_study_id>
    <nct_id>NCT02377661</nct_id>
  </id_info>
  <brief_title>Lowering Blood Pressure in Primary Care in Vienna</brief_title>
  <acronym>Low BP Vienna</acronym>
  <official_title>Lowering Blood Pressure in Primary Care in Vienna</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilhelminenspital Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association for the Promotion of Research in Atherosclerosis, Thrombosis and Vascular Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig Boltzmann Foundation for Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wilhelminenspital Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance
      blood pressure control in primary care by introducing a standardised and simplified titration
      regime with single pill combinations (SPC), comprising an angiotensin receptor blocker,
      calcium channel blocker and hydrochlorothiazide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Hypertension is the single largest contributor to mortality worldwide, accounting
      for 13% of deaths globally. Approximately 30% of the adult population suffer from
      hypertension and of those diagnosed and treated, only 30-50% have adequately controlled blood
      pressure. At present, the importance of hypertension as fundamental risk factors is
      inadequately addressed among many patients and physicians.

      Design The aim of this prospective, randomised, open-label, multicentre clinical trial is to
      enhance blood pressure control in primary care by introducing a standardised and simplified
      titration regime with single pill combinations (SPC), comprising an angiotensin receptor
      blocker, calcium channel blocker and hydrochlorothiazide.

      The trial will randomise 42 family doctors or resident specialists for internal medicine
      (enrolling 840 patients with treated or untreated hypertension) to either experimental care
      or standard care for hypertension, latter according to the 2013 European Society of
      Cardiology Guidelines for the Management of Arterial Hypertension.

      Practitioners randomised to experimental care will up-titrate antihypertensive therapy with
      SPCs in 4-week intervals if the target blood pressure of &lt; 140/90 mmHg is not reached at the
      respective follow-up (Figure 1).

      Study Outcomes The primary efficacy endpoint will be the proportion of patients achieving the
      target office blood pressure after 6 months of follow-up. The main secondary endpoint will be
      the improvement of 24h ambulatory blood pressure (ABPM) profile, measured at inclusion and
      after 6 months of follow-up.

      Safety assessments include the evaluation of treatment emergent adverse events, particularly
      hospitalisation, worsening of renal function, peripheral oedema and hypotension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">May 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of the target office blood pressure (&lt; 140/90 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving the target office blood pressure of 140/90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of the target systolic office blood pressure (&lt; 140 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving the target systolic office blood pressure of 140 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of the target diastolic office blood pressure (&lt; 90 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving the target diastolic office blood pressure of 90 mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of the target average 24h systolic ambulatory blood pressure (&lt; 130 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Average 24h systolic ambulatory blood pressure reading below 130 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the target average 24h diastolic ambulatory blood pressure (&lt; 80 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Average 24h diastolic ambulatory blood pressure reading below 80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the target average daytime systolic ambulatory blood pressure (&lt; 135 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Average daytime systolic ambulatory blood pressure reading below 135 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the target average nighttime systolic ambulatory blood pressure (&lt; 120 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Average nighttime systolic ambulatory blood pressure reading below 120 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the target average daytime diastolic ambulatory blood pressure (&lt; 85 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Average daytime diastolic ambulatory blood pressure reading below 85 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the target average nighttime diastolic ambulatory blood pressure (&lt; 70 mmHg)</measure>
    <time_frame>6 months</time_frame>
    <description>Average nighttime diastolic ambulatory blood pressure reading below 70 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment of hypertension according to current guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil, amlodipine, hydrochlorothiazide</intervention_name>
    <description>Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of &lt; 140/90 mmHg is not reached at the respective follow-up</description>
    <arm_group_label>Experimental Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  office blood pressure â‰¥ 140/90 mmHg

          -  ACE inhibitor intolerance (experimental arm)

        Exclusion Criteria:

          -  Malignant disease with life expectancy &lt; 6 months

          -  Women of childbearing potential (ICH definition) or breastfeeding

          -  Contraindications or allergies against olmesartan, amlodipine or hydrochlorothiazide
             (experimental arm)

          -  Chronic kidney disease grade IV or V (eGFR &lt; 30 ml/min)

          -  Recent myocardial infarction or stroke within the preceding 3 months

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas W Weiss, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>3rd Medical Department, Cardiology and Intensive Care Medicine Wilhelminenhospital, 1160 Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GP practices</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wilhelminenspital Vienna</investigator_affiliation>
    <investigator_full_name>Thomas Weiss, MD, PhD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

